Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical firm, has announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference will take place from November 16-18, 2020, with CEO Arthur Sands presenting on November 17 at 3:20 p.m. EST. The Piper Sandler 32nd Annual Virtual Healthcare Conference will follow from December 1-3, 2020, featuring Sands on December 1. Both presentations will be available for 30 days afterward on Nurix's Events and Presentations page.
Nurix Therapeutics (NRIX) announced presentations at two significant upcoming events: the 5th Medicinal Chemistry & Protein Degradation Summit and the 62nd ASH Annual Meeting. Key highlights include data on their targeted protein degradation platform and preclinical data for NX-2127, aimed at treating B-cell malignancies. The summit presentation is by Senior Scientist Dan Robbins on November 16, focusing on new therapeutic discovery, while the ASH meeting will feature NX-2127's effects on B-cell malignancies on December 7.
Nurix Therapeutics (Nasdaq: NRIX) announced the resignation of Robert Tjian, Ph.D. from its Board of Directors, effective November 1, 2020. Dr. Tjian, who has been on the board since November 2016, will continue to support Nurix as the Chairman of its Scientific Advisory Board. His leadership is expected to guide Nurix's research on E3 ligases, a target class critical for developing therapies for cancer. The company aims to advance multiple drug candidates into clinical trials, enhancing its potential in cancer treatment.
Nurix Therapeutics Inc. (NRIX) reported its third-quarter financial results for 2020, highlighting a significant IPO that raised approximately $238.5 million in gross proceeds. Despite challenges from the COVID-19 pandemic, the company is on track for multiple IND filings, including upcoming submissions for its lead drug candidates NX-2127 and NX-1607. The net loss attributed to common stockholders was $18.5 million or ($0.59) per share, with total cash holdings reaching $395.1 million as of August 31, 2020, indicating a strong financial position to support ongoing clinical development.
Nurix Therapeutics, Inc. (NASDAQ: NRIX) will present at the 3rd Targeted Protein Degradation Summit on October 14, 2020, at 1:50 p.m. EDT. The session, titled Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels, will be led by CEO Arthur Sands, M.D., Ph.D. Nurix focuses on developing small molecule therapies to modulate cellular protein levels, aiming to treat cancer and immune disorders. Their integrated discovery platform, DELigase, identifies and advances drug candidates targeting E3 ligases.
Nurix Therapeutics announced the pricing of its initial public offering of 11,000,000 shares at $19.00 per share, aiming for gross proceeds of approximately $209 million.
The shares are set to trade on The Nasdaq Global Market under the symbol NRIX starting July 24, 2020. Additionally, underwriters have a 30-day option to buy up to 1,650,000 more shares at the IPO price. The offering is expected to close by July 28, 2020, pending customary closing conditions.